Ana Alfonso Piérola

Author

Ana Alfonso Piérola

Also Known As

A Alfonso, A. Alfonso, A. Alfonso Pierola, A. Alfonso Piérola, A. Alfonso-Pierola, A. Alfonso‐Pierola, Ana A. Pierola, Ana Alfonso, Ana Alfonso Pierola, Ana Alfonso Piérola

190

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Clinica Universidad de Navarra The University of Texas MD Anderson Cancer Center Universidad de Navarra Centro de Investigación Biomédica en Red de Cáncer Vall d'Hebron Hospital Universitari

About

Ana Alfonso Piérola is an author at Clinica Universidad de Navarra specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	891
2	Health Sciences	4	4	486
3	Public Health	3	3	160
4	Cell Biology	2	2	154
5	Biochemistry	1	1	12

Ana Alfonso Piérola

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial Paul G. Richardson, Albert Oriol, Meral Beksaç, The Lancet Oncology Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy	2019	375
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms David P. Steensma, Martin Wermke, Virginia M. Klimek, Leukemia	2021	169
Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism Ana Alfonso Piérola, David Jiménez, Carmen Fernández Capitán, Thrombosis and Haemostasis Recurrent VtePharmacotherapyLogistic AnalysisThrombosisVenous Thrombosis	2013	122
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome Paula Rodríguez-Márquez, María Eréndira Calleja-Cervantes, Guillermo Serrano, Science Advances T-regulatory CellImmunologyAntitumoral EfficacyCar DensityImmunotherapy	2022	107
RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study Carmelo Carlo‐Stella, Rita Mazza, Salomon Manier, Blood	2022	86
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy Irene Gañán‐Gómez, Hui Yang, Feiyang Ma, Nature Medicine	2022	76
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms Guillermo Montalban‐Bravo, Koichi Takahashi, Keyur P. Patel, Oncotarget	2018	63
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution Marina Ainciburu, Teresa Ezponda, Nerea Berastegui, eLife	2023	60
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies Yasmin Abaza, Tapan M. Kadia, Elias Jabbour, Cancer	2017	55
CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Blood Lymphoid NeoplasiaImmunologyCell TransplantationImmune Cell TherapyImmunotherapy	2022	47

Page 1